IGF2: the Achilles' heel of p53-deficiency?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Synthetic lethality prediction in DNA damage repair, chromatin remodeling and the cell cycle using multi-omics data from cell lines and patients.Scientific reports · 2023
   Article
2. Unraveling the IGF System Interactome in Sarcomas Exploits Novel Therapeutic Options.Cells · 2021
   Review
3. Isoform- and Paralog-Switching in IR-Signaling: When Diabetes Opens the Gates to Cancer.Biomolecules · 2020
   Review
4. Rapamycin-independent IGF2 expression in Tsc2-null mouse embryo fibroblasts and human lymphangioleiomyomatosis cells.PloS one · 2018
   Article
5. Antitumor mechanisms when pRb and p53 are genetically inactivated.Oncogene · 2015
   Review
6. Notch signaling in hepatocellular carcinoma: guilty in association!Gastroenterology · 2012
   Article

Corrections and comments

• Comment on
  Igf2 pathway dependency of the Trp53 developmental and tumour phenotypes.2012

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as